TransMedics stock surged 21% after reporting Q1 revenue of $143.5M—up 48% YoY—and EPS of 70¢, crushing the 29¢ consensus. The company raised full-year revenue guidance to $565M–$585M, citing strong demand for its OCS transplant platform.
CEO Dr. Waleed Hassanein highlighted momentum in organ perfusion and logistics, noting a growing aircraft fleet and a new facility in Italy focused on perfusion innovation. Despite upcoming FDA decisions on new programs, TransMedics doesn’t expect major 2025 impact.
Tariffs pose minimal risk for now.
Follow MEDWIRE.AI for MedTech earnings and transplant tech news.
